Science for Life.
Commitment for Every Tomorrow.

Neurology

Supporting the Brain, Nerves, and Everyday Independence

The nervous system controls movement, sensation, memory, mood, balance, and many other essential functions. Neurological medicines work through different mechanisms—regulating electrical activity in the brain, modifying chemical messengers, improving blood flow, or supporting nerve-cell health.

Neuropathic Pain

Neuropathic pain develops when nerves are damaged or send abnormal pain signals to the brain.

Pregabalin and Gabapentin attach to the alpha-2-delta subunit of voltage-gated calcium channels. This reduces the release of excitatory neurotransmitters and helps calm excessive nerve signalling.

Duloxetine, Amitriptyline, and Nortriptyline increase the availability of serotonin and noradrenaline in pain-modulating pathways. These chemical messengers help the brain and spinal cord regulate how pain signals are processed.

Methylcobalamin, an active form of vitamin B12, supports normal nerve-cell metabolism and myelin formation. Alpha Lipoic Acid provides antioxidant activity that may help protect nerve tissue from oxidative stress.

Compositions in our portfolio:

• Pregabalin
• Pregabalin + Methylcobalamin
• Pregabalin + Nortriptyline
• Pregabalin + Methylcobalamin + Nortriptyline
• Gabapentin
• Gabapentin + Methylcobalamin
• Duloxetine
• Amitriptyline
• Nortriptyline
• Methylcobalamin
• Methylcobalamin + Alpha Lipoic Acid + B Vitamins

Epilepsy Management

Seizures occur when groups of brain cells produce sudden, excessive, or synchronised electrical activity. Anti-epileptic medicines help stabilise this activity through different molecular pathways.

Levetiracetam binds to synaptic vesicle protein SV2A and modifies neurotransmitter release. Sodium Valproate and Valproic Acid increase inhibitory GABA activity while also influencing sodium and calcium channels.

Lamotrigine and Oxcarbazepine primarily stabilise voltage-sensitive sodium channels. Topiramate acts through several mechanisms, including sodium-channel regulation, enhancement of GABA activity, and reduction of excitatory glutamate signalling.

Lacosamide promotes slow inactivation of sodium channels, while Clobazam strengthens the inhibitory action of GABA.

Compositions in our portfolio:

• Levetiracetam Tablets and Oral Solution
• Sodium Valproate
• Sodium Valproate Controlled Release
• Sodium Valproate + Valproic Acid
• Lamotrigine
• Oxcarbazepine
• Topiramate
• Lacosamide
• Clobazam

Migraine Care

Migraine involves altered nerve signalling and activation of pain-sensitive pathways around the brain.

Sumatriptan and Rizatriptan stimulate selected serotonin receptors, helping reduce the release of pain-related neuropeptides and activity within the trigeminal pain pathway.

Propranolol and Flunarizine may reduce the sensitivity of migraine-related pathways when used as preventive therapies. Naproxen reduces prostaglandin production and associated pain and inflammation, while Domperidone helps control migraine-associated nausea and vomiting.

Compositions in our portfolio:

• Flunarizine
• Propranolol
• Sumatriptan
• Rizatriptan
• Naproxen + Domperidone

Vertigo and Balance Disorders

Vertigo may result from disturbances in the inner ear or the neural pathways responsible for balance.

Betahistine acts mainly through histamine-related pathways and may support microcirculation within the inner ear. Cinnarizine reduces calcium entry into certain cells and can decrease vestibular sensitivity.

Dimenhydrinate suppresses excessive signals from the vestibular system and helps relieve associated nausea. Ginkgo Biloba is used in selected formulations for its potential effects on circulation and antioxidant protection, although clinical suitability depends on the individual patient.

Compositions in our portfolio:

• Betahistine
• Betahistine + Ginkgo Biloba
• Cinnarizine
• Cinnarizine + Dimenhydrinate

Parkinson’s Disease

Parkinson’s disease is associated with reduced dopamine activity in brain regions responsible for controlled movement.

Levodopa crosses into the brain and is converted into dopamine. Carbidopa reduces the breakdown of levodopa outside the brain, allowing more of it to reach its target. Entacapone further prolongs levodopa availability by inhibiting the COMT enzyme.

Pramipexole and Ropinirole directly stimulate dopamine receptors. Amantadine can enhance dopaminergic activity and influence glutamate signalling. Trihexyphenidyl reduces excessive cholinergic activity and may help manage selected movement symptoms.

Compositions in our portfolio:

• Levodopa + Carbidopa
• Levodopa + Carbidopa + Entacapone
• Pramipexole
• Ropinirole
• Amantadine
• Trihexyphenidyl

Cognitive and Neuro Support

Cognitive therapies act on pathways involved in memory, neuronal communication, and brain-cell function.

Donepezil inhibits acetylcholinesterase, increasing acetylcholine availability in the brain. Memantine regulates excessive NMDA-receptor activity associated with abnormal glutamate signalling.

Citicoline supplies components involved in neuronal membrane synthesis. Piracetam is thought to influence neuronal membrane function and neurotransmission, although approved uses and supporting evidence vary between countries.

Compositions in our portfolio:

• Citicoline
• Citicoline + Piracetam
• Piracetam
• Donepezil
• Donepezil + Memantine
• Memantine

Cardiology

Supporting the Heart and Vascular System

Cardiovascular medicines work by controlling blood pressure, regulating heart rate, reducing cholesterol, preventing unwanted blood clots, improving circulation, and reducing the workload placed on the heart.

Hypertension Management

Telmisartan, Olmesartan, and Losartan block angiotensin II AT1 receptors. This prevents excessive narrowing of blood vessels and reduces aldosterone-related sodium and water retention.

Amlodipine and Cilnidipine reduce calcium entry into vascular smooth-muscle cells, allowing blood vessels to relax.

Hydrochlorothiazide and Chlorthalidone increase the removal of sodium and water through the kidneys, helping reduce circulating fluid volume and blood pressure.

Combination formulations act through complementary pathways to provide broader blood-pressure control when clinically appropriate.

Compositions in our portfolio:

• Telmisartan
• Telmisartan + Amlodipine
• Telmisartan + Hydrochlorothiazide
• Telmisartan + Chlorthalidone
• Telmisartan + Metoprolol
• Telmisartan + Cilnidipine
• Olmesartan
• Olmesartan + Amlodipine
• Losartan
• Losartan + Hydrochlorothiazide
• Amlodipine
• Cilnidipine
• Amlodipine + Atenolol

Heart-Rate and Workload Control

Metoprolol, Bisoprolol, Nebivolol, Atenolol, and Carvedilol block selected beta-adrenergic receptors. This reduces the effects of stress hormones on the heart, slowing heart rate and decreasing cardiac workload.

Nebivolol may additionally promote nitric-oxide-mediated vasodilation. Carvedilol also blocks alpha-1 receptors, supporting further relaxation of blood vessels.

Compositions in our portfolio:

• Metoprolol Succinate Extended Release
• Bisoprolol
• Nebivolol
• Nebivolol + Amlodipine
• Carvedilol
• Amlodipine + Atenolol

Lipid Management and Vascular Protection

Rosuvastatin and Atorvastatin inhibit the HMG-CoA reductase enzyme in the liver. This reduces cholesterol production and increases the liver’s removal of LDL cholesterol from the blood.

Fenofibrate activates PPAR-alpha receptors, promoting the breakdown of triglyceride-rich particles. Statin–fenofibrate combinations may therefore address different components of abnormal lipid levels in appropriately selected patients.

Some formulations combine statins with antiplatelet medicines to address both lipid control and clot-related cardiovascular risk.

Compositions in our portfolio:

• Rosuvastatin
• Rosuvastatin + Fenofibrate
• Rosuvastatin + Aspirin
• Rosuvastatin + Clopidogrel
• Rosuvastatin + Aspirin + Clopidogrel
• Atorvastatin
• Atorvastatin + Aspirin
• Atorvastatin + Clopidogrel

Antiplatelet Therapy

Platelets help stop bleeding, but inappropriate platelet activation can contribute to arterial clots.

Aspirin irreversibly inhibits COX-1 and reduces thromboxane A2 production. Clopidogrel and Ticagrelor block P2Y12-mediated platelet activation through different binding mechanisms.

Cilostazol inhibits phosphodiesterase-3, reducing platelet aggregation while also promoting vasodilation.

Compositions in our portfolio:

• Aspirin
• Clopidogrel
• Aspirin + Clopidogrel
• Ticagrelor
• Cilostazol

Anticoagulation

Anticoagulants act on the blood-clotting cascade rather than directly on platelets.

Apixaban and Rivaroxaban directly inhibit activated factor Xa. Dabigatran directly inhibits thrombin. These actions reduce the formation of fibrin, a structural component of blood clots.

Compositions in our portfolio:

• Apixaban
• Rivaroxaban
• Dabigatran

Heart Failure Care

Heart failure therapies work through complementary mechanisms to reduce cardiac workload, regulate fluid balance, and improve the heart’s efficiency.

Sacubitril prevents the breakdown of beneficial natriuretic peptides, while Valsartan blocks angiotensin II receptors. Together, they support vasodilation and reduce sodium and fluid retention.

Spironolactone and Eplerenone block mineralocorticoid receptors, limiting the effects of aldosterone. Ivabradine acts on the heart’s funny current, or If current, to reduce heart rate without directly reducing the strength of contraction.

Dapagliflozin and Empagliflozin inhibit SGLT2 in the kidneys, increasing urinary glucose and sodium excretion. Their cardiovascular effects extend beyond glucose reduction and include favourable changes in fluid balance and cardiac–renal physiology.

Compositions in our portfolio:

• Sacubitril + Valsartan
• Spironolactone
• Eplerenone
• Ivabradine
• Dapagliflozin
• Empagliflozin

Angina Management

Angina occurs when the heart muscle does not receive enough oxygen for its workload.

Isosorbide Mononitrate releases nitric oxide, relaxing blood vessels and reducing the workload on the heart. Ranolazine inhibits the late sodium current in cardiac cells, helping improve relaxation and reduce oxygen demand.

Trimetazidine modifies cardiac energy metabolism so the heart can generate energy more efficiently under reduced-oxygen conditions.

Compositions in our portfolio:

• Ranolazine
• Trimetazidine Modified Release
• Isosorbide Mononitrate

Oncology

Science-Led Support Across the Cancer-Care Journey

Cancer is not a single disease. It includes many conditions driven by different genetic and cellular mechanisms. Our oncology focus presented here covers oral anticancer medicines, injectable oncology therapies, and supportive care used during demanding treatment journeys.

Oral Anticancer Therapy

Oral anticancer medicines act through several mechanisms.

Capecitabine is converted in the body into fluorouracil, which interferes with DNA production. Temozolomide damages tumour-cell DNA through alkylation.

Hydroxyurea inhibits ribonucleotide reductase and reduces the supply of building blocks needed for DNA synthesis. Cyclophosphamide and Etoposide interfere with DNA integrity or replication.

Lenalidomide and Thalidomide have immunomodulatory, anti-angiogenic, and tumour-related effects that vary by disease setting.

Compositions in our portfolio:

• Capecitabine
• Temozolomide
• Hydroxyurea
• Lenalidomide
• Thalidomide
• Etoposide Capsules
• Cyclophosphamide Tablets

Injectable Oncology Therapies

Injectable anticancer medicines target different stages of cell growth and division.

Paclitaxel and Docetaxel stabilise microtubules and interfere with cell division. Cisplatin, Carboplatin, and Oxaliplatin form platinum–DNA bonds that disrupt replication.

Gemcitabine, Fluorouracil, Pemetrexed, and Methotrexate interfere with nucleotide metabolism or DNA synthesis. Doxorubicin and Epirubicin damage DNA through topoisomerase inhibition and other cellular effects.

Irinotecan and Etoposide inhibit topoisomerase enzymes required for DNA replication. Cyclophosphamide alkylates DNA, while Bortezomib inhibits the proteasome and disrupts protein regulation within susceptible cancer cells.

Compositions in our portfolio:

• Paclitaxel
• Docetaxel
• Carboplatin
• Cisplatin
• Oxaliplatin
• Gemcitabine
• Pemetrexed
• Doxorubicin
• Epirubicin
• Cyclophosphamide
• Bortezomib
• Fluorouracil
• Irinotecan
• Etoposide
• Methotrexate

Supportive Oncology Care

Supportive therapies help manage treatment-related symptoms and complications.

Ondansetron and Palonosetron block serotonin 5-HT3 receptors involved in nausea and vomiting. Aprepitant and Fosaprepitant block neurokinin-1 receptors and help control substance-P-mediated vomiting pathways.

Zoledronic Acid reduces excessive bone breakdown by inhibiting osteoclast activity. Filgrastim and Pegfilgrastim stimulate the bone marrow to produce neutrophils.

Calcium, Vitamin D3, iron and haematinic formulations, and nutritional protein supplements may be used to address identified nutritional or haematological needs under professional supervision.

Compositions in our portfolio:

• Ondansetron
• Palonosetron
• Aprepitant
• Fosaprepitant
• Zoledronic Acid
• Filgrastim
• Pegfilgrastim
• Calcium + Vitamin D3
• Iron and Haematinic Formulations
• Nutritional Protein Supplements